Victory Capital Management Inc Ultragenyx Pharmaceutical Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

A detailed history of Victory Capital Management Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 10,948 shares of RARE stock, worth $489,923. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,948

Previous 10,064 8.78%

Holding current value

$489,923

Previous $413,000 47.22%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$40.21 - $59.36 $35,545 - $52,474	884 Added 8.78%	10,948 $608,000
Q2 2024 Aug 05, 2024	SELL	$37.42 - $51.61 $3,554 - $4,902	-95 Reduced 0.94%	10,064 $413,000
Q1 2024 May 03, 2024	SELL	$43.02 - $53.69 $17,466 - $21,798	-406 Reduced 3.84%	10,159 $474,000
Q4 2023 Feb 05, 2024	BUY	$31.73 - $49.19 $103,408 - $160,310	3,259 Added 44.61%	10,565 $505,000
Q3 2023 Nov 06, 2023	BUY	$34.92 - $46.66 $5,447 - $7,278	156 Added 2.18%	7,306 $260,000
Q2 2023 Jul 27, 2023	SELL	$37.35 - $52.15 $6,237 - $8,709	-167 Reduced 2.28%	7,150 $329,000
Q1 2023 May 02, 2023	SELL	$36.99 - $48.71 $2,774 - $3,653	-75 Reduced 1.01%	7,317 $293,000
Q4 2022 Feb 10, 2023	BUY	$33.72 - $46.33 $2,225 - $3,057	66 Added 0.9%	7,392 $342,000
Q4 2022 Feb 09, 2023	SELL	$33.72 - $46.33 $2,326 - $3,196	-69 Reduced 0.93%	7,326 $339,000
Q3 2022 Nov 02, 2022	SELL	$39.96 - $66.14 $2,917 - $4,828	-73 Reduced 0.98%	7,395 $306,000
Q2 2022 Aug 01, 2022	BUY	$45.8 - $85.4 $412 - $768	9 Added 0.12%	7,468 $446,000
Q1 2022 May 04, 2022	BUY	$62.2 - $84.4 $1,306 - $1,772	21 Added 0.28%	7,459 $527,000
Q4 2021 Feb 07, 2022	BUY	$73.71 - $87.86 $60,663 - $72,308	823 Added 12.44%	7,438 $625,000
Q3 2021 Nov 02, 2021	BUY	$77.92 - $102.4 $34,908 - $45,875	448 Added 7.26%	6,615 $597,000
Q2 2021 Aug 03, 2021	SELL	$92.19 - $115.71 $23,047 - $28,927	-250 Reduced 3.9%	6,167 $588,000
Q1 2021 May 04, 2021	SELL	$106.9 - $167.73 $36,666 - $57,531	-343 Reduced 5.07%	6,417 $731,000
Q4 2020 Feb 01, 2021	BUY	$84.4 - $177.39 $172,176 - $361,875	2,040 Added 43.22%	6,760 $936,000
Q3 2020 Nov 09, 2020	SELL	$72.98 - $90.0 $22,185 - $27,360	-304 Reduced 6.05%	4,720 $388,000
Q2 2020 Aug 07, 2020	SELL	$46.91 - $78.22 $13,650 - $22,762	-291 Reduced 5.48%	5,024 $393,000
Q1 2020 May 04, 2020	SELL	$33.8 - $62.9 $70,473 - $131,146	-2,085 Reduced 28.18%	5,315 $236,000
Q4 2019 Feb 06, 2020	BUY	$36.08 - $45.83 $49,068 - $62,328	1,360 Added 22.52%	7,400 $316,000
Q4 2019 Feb 04, 2020	SELL	$36.08 - $45.83 $9,849 - $12,511	-273 Reduced 4.32%	6,040 $317,000
Q3 2019 Nov 12, 2019	BUY	$42.5 - $63.11 $268,302 - $398,413	6,313 New	6,313 $270,000
Q4 2018 Feb 05, 2019	SELL	$38.89 - $77.3 $19,833 - $39,423	-510 Closed	0 $0
Q3 2018 Nov 01, 2018	BUY	$71.81 - $90.15 $4,811 - $6,040	67 Added 15.12%	510 $39,000
Q2 2017 Aug 07, 2017	BUY	N/A	443	443 $28,000

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Ultragenyx Pharmaceutical Inc. Transaction History